On the other hand, the modulation of immune cells occurring in HER2+ BC has shown a clinical impact on treatment efficacy, and due to the promising role of immunotherapy in HER2+ BC, different immune checkpoint inhibitors and other immunotherapeutic agents are being tested in clinical trials opening new possibilities for therapeutic combinations in this setting. Here, ERBB2 is linked to breast cancer.